In KBM-5 myeloid leukemia cells and in MDA-MB-231 breast cancer cells, NF-κB activation was not significantly inhibited by gossypetin, thus questioning the role of gossypetin as an NF-κB pathway inhibitor in these cell lines [74,75]. Here, NFKB1 is linked to breast carcinoma.